Cancer News and Research

Latest Cancer News and Research

Abraxis BioScience reports $96.6 million net revenues for third quarter of 2009

Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the third quarter ending September 30, 2009.

5 Nov 2009

FDA grants Abraxis BioScience orphan drug designation for ABRAXANE

Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted orphan drug designation to the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of pancreatic cancer as well as stage IIB-IV melanoma.

5 Nov 2009

ARIAD Pharmaceuticals' SUCCEED trial of oral ridaforolimus on track

ARIAD Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009 and provided an update on corporate developments.

5 Nov 2009

New biosensor device may help in combating cancer

A powerful new biosensor developed by European researchers will help identify cells in the immune system that actively suppress tumour growth, then put them to use. Enlisting the patient's own immune system would be like sending reinforcements for resistance fighters.

5 Nov 2009

Oncolytics Biotech reports financial results for the third quarter of 2009

Oncolytics Biotech Inc. today announced its financial results for the three and nine-month periods ended September 30, 2009.

5 Nov 2009

ArQule reports financial results for the fiscal quarter and nine months ended September 30, 2009

ArQule, Inc. today reported its results of operations for the fiscal quarter and nine months ended September 30, 2009.

5 Nov 2009

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009.

5 Nov 2009

Arrayit joins federal government to help control health care costs through early diagnosis of diseases

Arrayit Corporation is pleased to join the federal government in their efforts to help control health care costs through early diagnosis of diseases.

5 Nov 2009

First Edition: November 5, 2009

Today's headlines center on the House health overhaul vote scheduled for Saturday -- what some are calling a potentially 'historic moment' for Democrats.

5 Nov 2009

American Shared Hospital Services reports financial results for the third quarter of 2009

AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today announced financial results for the third quarter and first nine months of 2009.

5 Nov 2009

Phase Forward, Quotient Clinical sign multi-year agreement

Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, today announced a multi-year agreement with Quotient Clinical, which specializes in early development services for a broad range of pharmaceutical and biotech customers.

5 Nov 2009

Scientists identify molecular disparity between iPS cells and embryonic stem cells

The same genes that are chemically altered during normal cell differentiation, as well as when normal cells become cancer cells, are also changed in stem cells that scientists derive from adult cells, according to new research from Johns Hopkins and Harvard.

5 Nov 2009

Plant carotenoids are the most important source of vitamin A in the human diet

Carotenoids-fat-soluble plant compounds found in some vegetables-are essential to the human diet and reportedly offer important health benefits to consumers. Plant carotenoids are the most important source of vitamin A in the human diet; the carotenoids lutein and zeaxanthin, found in corn and leafy greens vegetable such as kale, broccoli, and spinach, are widely considered to be valuable antioxidants capable of protecting humans from chronic diseases including age-related macular degeneration, cancer, and cardiovascular disease.

5 Nov 2009

Cell Therapeutics reports financial results for the third quarter and nine months ended September 30, 2009

Cell Therapeutics, Inc. today reported recent achievements and financial results for the third quarter and nine months ended September 30, 2009, which included a 45% decrease in the net loss attributable to common shareholders for the nine month period in 2009 compared to the same period in 2008.

5 Nov 2009

Study suggests three-week course of radiation therapy effective for breast cancer patients

According to a study presented November 4, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO), a shortened, more intensive course of radiation given to the whole breast, along with an extra dose of radiation given to the surgical bed of the tumor (concomitant boost), has been shown to result in excellent local control at a median follow up of two years after treatment with no significant side effects.

5 Nov 2009

Abraxis Health dedicates its new manufacturing facility in Phoenix

Abraxis Health, a fully-integrated personalized healthcare division of Abraxis BioScience, Inc., today announced the dedication of its new manufacturing facility in Phoenix, Arizona. The state of the art biopharma manufacturing plant represents a $70 million investment by LA-based Abraxis, and will create up to 200 high tech jobs.

5 Nov 2009

Evidence continues to grow about green tea's cancer prevention properties

Although scientists are reluctant to officially endorse green tea as a cancer prevention method, evidence continues to grow about its protective effects, including results of a new study published in Cancer Prevention Research, a journal of the American Association for Cancer Research, which suggests some reduction in oral cancer.

5 Nov 2009

Short, intensive radiation therapy offers similar results as conventional therapy for early stage-breast cancers

5 Nov 2009

Bursting common myths about psoriasis

Psoriasis is a real disability that affects approximately one million Canadians. A recent Canadian survey found that the causes and effects of this chronic, recurrent skin disorder are often misunderstood - and the result of these misperceptions can leave a lasting negative impact on those who suffer from this debilitating immune system disease.

5 Nov 2009

New therapeutic approach targets cancer cells, not normal cells

The ultimate goal in cancer research, a treatment that kills cancer cells whilst leaving healthy cells untouched, is brought nearer by the success of a new therapeutic approach. The potential therapy, published in BioMed Central's open access journal Breast Cancer Research, targets proliferation of cancer, but not normal, cells.

5 Nov 2009

Cancer News and Research

Latest Cancer News and Research

Abraxis BioScience reports $96.6 million net revenues for third quarter of 2009

FDA grants Abraxis BioScience orphan drug designation for ABRAXANE

ARIAD Pharmaceuticals' SUCCEED trial of oral ridaforolimus on track

New biosensor device may help in combating cancer

Oncolytics Biotech reports financial results for the third quarter of 2009

ArQule reports financial results for the fiscal quarter and nine months ended September 30, 2009

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Arrayit joins federal government to help control health care costs through early diagnosis of diseases

First Edition: November 5, 2009

American Shared Hospital Services reports financial results for the third quarter of 2009

Phase Forward, Quotient Clinical sign multi-year agreement

Scientists identify molecular disparity between iPS cells and embryonic stem cells

Plant carotenoids are the most important source of vitamin A in the human diet

Cell Therapeutics reports financial results for the third quarter and nine months ended September 30, 2009

Study suggests three-week course of radiation therapy effective for breast cancer patients

Abraxis Health dedicates its new manufacturing facility in Phoenix

Evidence continues to grow about green tea's cancer prevention properties

Short, intensive radiation therapy offers similar results as conventional therapy for early stage-breast cancers

Bursting common myths about psoriasis

New therapeutic approach targets cancer cells, not normal cells

Cancer Research - Second Edition eBook

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Newsletters you may be interested in